Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the <scp>SURMOUNT</scp> ‐1 study
Tirzepatide treatment was associated with improved HRQoL compared to placebo in people with overweight or obesity. Higher percentages of weight reduction were associated with greater improvements. Clinical trial registration number for SURMOUNT-1: NCT04184622.
Authors
- Donna Mojdami
- Jiat Ling Poon (ORCID: https://orcid.org/0000-0001-7038-2102)
- Kimberly A. Gudzune (ORCID: https://orcid.org/0000-0002-7782-1769)
- Nadia Ahmad (ORCID: https://orcid.org/0000-0003-3607-0740)
- Dachuang Cao (ORCID: https://orcid.org/0000-0003-2291-9037)
- Fangyu Wang
- Adam Stefański (ORCID: https://orcid.org/0009-0001-7598-402X)
Institutions
- Johns Hopkins University (US)
- Eli Lilly (United States) (US)
- Johns Hopkins Medicine (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1111/dom.16046
- Citations
- 32
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 11.45
Funders
- Eli Lilly and Company